TP53 and colorectal carcinoma: Loss or mutation of RPL22, which is rather frequent in CRC, interferes with the MDM4–p53 axis and leads to increased full-length MDM4, suppression of p53, and enhanced cell growth and drug resistance [131,135,136,137].